Too Many Pancreatic Cancer Patients Not Offered Surgery
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, July 28, 2023 -- Surgery is underutilized for the treatment of resectable pancreatic ductal adenocarcinoma (PDAC) in Texas, according to a study recently published in the Journal of Surgical Oncology.
Gilbert Z. Murimwa, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues used data from the Texas Cancer Registry to identify resectable PDAC patients who underwent curative-intent surgery between 2004 and 2018. Demographic and clinical factors associated with failure to operate and survival were evaluated.
The researchers found that among 4,274 identified patients, 22 percent underwent resection, 57 percent were not offered surgery, 6 percent had comorbidities precluding surgery, and 3 percent refused. During the study period, the resection rates decreased from 31 percent in 2004 to 22 percent in 2018. There were significant associations observed between increasing age and failure to operate (odds ratio, 2.55) and treatment at a Commission on Cancer center with reduced failure to operate (odds ratio, 0.63). There were significant associations between survival and resection (hazard ratio for death, 0.34) and treatment at a National Cancer Institute-designated center (hazard ratio for death, 0.79).
"We are failing nearly 80 percent of patients eligible for surgical resection, which can significantly extend survival or potentially even be curative in combination with chemotherapy," coauthor Patricio Polanco, M.D., also from the University of Texas Southwestern Medical Center, said in a statement. "Many patients think that this is always an incurable disease and don’t pursue aggressive treatment."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among...
Odds of Death Lower With Surgery for Hip Fracture in Patients With Dementia
MONDAY, June 3, 2024 -- For community-dwelling patients with dementia and fracture of the femoral head and neck, the odds of death are lower for those treated surgically...
Emergency Inguinal Hernia Surgery Rates Increased With Lower Country Income
FRIDAY, May 31, 2024 -- For patients undergoing inguinal hernia surgery, emergency surgery rates increase from high- to low-income countries, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.